Rapid Health Technology Assessment of Albumin-bound Paclitaxel in the Treatment of Breast Cancer
- VernacularTitle:白蛋白结合型紫杉醇治疗乳腺癌的快速卫生技术评估
- Author:
Jiemei JIANG
1
,
2
;
Yalu WANG
3
;
Chunlan YANG
1
;
Lijuan FENG
1
;
Ruonan CHEN
1
;
Xi CAO
1
;
Peng MEN
4
,
5
;
Yiheng YANG
4
,
5
;
Suodi ZHAI
4
,
5
;
Quan XIA
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Anhui Medical University，Hefei 230022，China
2. Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine，Hefei 230022，China
3. School of Pharmacy，Anhui Medical University，Hefei 230032，China
4. Dept. of Pharmacy，Peking University Third Hospital，Beijing 100191，China
5. Center for Drug Evaluation，Peking University H ealth Science Center，Beijing 100191，China
- Publication Type:Journal Article
- Keywords:
Albumin-bound paclitaxel;
Breast cancer;
Rapid health technology assessment;
Effectiveness;
Safety;
Economics
- From:
China Pharmacy
2021;32(13):1611-1616
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To evaluate th e effectiveness ，safety and economy of albu min-bound paclitaxel （nab-PTX）in the treatment of breast cancer by using rapid health technology assessment （HTA），and to provide evidence-based reference for drug selection. METHODS ：Retrieved from PubMed ，the Cochrane Library ，CNKI，Wangfang database and other databases ，systematic evaluation/Meta-analysis，HTA and pharmacoeconomic studies about nab-PTX in the treatment of breast cancer were included ；the conclusions were classified and analyzed by using descriptive analysis. RESULTS ：A total of 5 systematic reviews/Meta-analysis ， 8 pharmacoeconomic studies were included in this study. Compared with conventional taxanes ，nab-PTX increased pathological complete response （pCR）rate [OR ＝1.39，95％CI（1.16，1.67），P＜0.001] and event-free survival （EFS）[HR＝0.69，95％CI（0.57， 0.85），P＜0.001] in neoadjuvant chemotherapy （NAC）-treated breast cancer patients. However ，there were no significant differences in overall survival （OS），progression-free survival （PFS），objective response rate （ORR）and disease control rate （DCR）in metastatic breast cancer （MBC）patients between 2 groups. In the terms of safety ，nab-PTX increased the incidence of grade 3-4 sensory neuropathy [OR ＝1.89，95％CI（1.36，2.61），P＜0.001] in MBC patients ，and increased the incidence of neutropenia [OR ＝ 1.52，95％CI（1.23，1.88，P＜0.001]，sensory neuropathy [OR ＝ 2.17，95％CI（1.38，3.40），P＜0.001]，rash [OR ＝1.46，95％CI mei1213@163.com （1.18，1.80），P＜0.001] and fatigue [OR ＝1.28，95％CI（1.04， 1.56）， P＝0.02] in NAC -treated breast cancer patients.Pharmacoeconomic studies showed that nab-PTX could improve the quality adjusted lif e years of MBC patients compared with traditional taxanes ，and it was a economical option. CONCLUSIONS：Nab-PTX enhances pCR in NAC-treated breast cancer patients ，but has no significant advantage in the effectiveness of MBC patients ，and increases the occurrence of ADR. Nab-PTX may have a cost-utility advantage over conventional taxanes for MBC.
